SYRA vs TALK

For growth investors, Talkspace, Inc.

(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). Talkspace, Inc. (TALK) offers the better valuation at 129. 8x trailing P/E (38. 3x forward), making it the more compelling value choice. Analysts rate Talkspace, Inc. (TALK) a "Hold" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Talkspace, Inc.

(TALK) delivered a total return of -47. 6%, compared to -85. 0% for Syra Health Corp. Class A Common Stock (SYRA). Over 10 years, the gap is even starker: TALK returned -48. 6% versus SYRA's -85. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Syra Health Corp.

Class A Common Stock (SYRA) is the lower-risk stock at 0. 19β versus Talkspace, Inc. 's 0. 86β — meaning TALK is approximately 361% more volatile than SYRA relative to the S&P 500.

By revenue growth (latest reported year), Talkspace, Inc.

(TALK) is pulling ahead at 22. 0% versus -9. 5% for Syra Health Corp. Class A Common Stock (SYRA). Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Talkspace, Inc.

(TALK) is the more profitable company, earning 3. 4% net margin versus -12. 4% for Syra Health Corp. Class A Common Stock — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TALK leads at 1. 4% versus -12. 5% for SYRA. At the gross margin level — before operating expenses — TALK leads at 43. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Syra Health Corp.

Class A Common Stock (SYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19)). Both have compounded well over 10 years (SYRA: -85. 0%, TALK: -48. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SYRA is a small-cap quality compounder stock; TALK is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.